1. Introduction {#sec1-jcm-09-01039}
===============

Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides life support for patients with refractory cardiogenic shock and significantly improves their survival working as a bridge to either recovery or other long-term treatments \[[@B1-jcm-09-01039],[@B2-jcm-09-01039],[@B3-jcm-09-01039],[@B4-jcm-09-01039],[@B5-jcm-09-01039],[@B6-jcm-09-01039],[@B7-jcm-09-01039],[@B8-jcm-09-01039],[@B9-jcm-09-01039]\].

A well recognized limitation of the retrograde aortic flow while on VA-ECMO is the increase of left ventricular (LV) afterload \[[@B10-jcm-09-01039]\], which can potentially lead to high LV stress and may exacerbate myocardial ischemia thus delaying recovery from cardiogenic shock \[[@B11-jcm-09-01039]\]. Elevated LV pressure can also promote LV dilatation and trigger ventricular arrhythmias, or, secondarily, increase left atrial pressure causing pulmonary edema \[[@B12-jcm-09-01039]\]. Ultimately, a reduced flow across the aortic valve can induce formation of thrombus in the LV or the aortic root \[[@B13-jcm-09-01039]\].

Several LV unloading strategies have been described and proposed in order to minimize the risk of these complications \[[@B14-jcm-09-01039]\], however, the available evidences are still conflicting whether these techniques are safe and useful adjuncts to VA-ECMO in patients with cardiogenic shock \[[@B15-jcm-09-01039],[@B16-jcm-09-01039],[@B17-jcm-09-01039],[@B18-jcm-09-01039]\].

The aim of this study was to comprehensively assess the impact on early outcomes of different strategies of LV unloading in patients undergoing VA-ECMO and sustaining advanced cardiogenic shock by various etiologies.

2. Experimental Section {#sec2-jcm-09-01039}
=======================

2.1. Data Sources and Search Strategy {#sec2dot1-jcm-09-01039}
-------------------------------------

This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@B19-jcm-09-01039]\]. The PRISMA checklist is available as [Appendix A](#app2-jcm-09-01039){ref-type="app"} [Table A1](#jcm-09-01039-t0A1){ref-type="table"}. Research of relevant studies was limited to the period January 2000--March 2019, through PubMed, EMBASE, CINAHL, the Cochrane Register of Controlled Clinical Trials (CENTRAL) and Google Scholar. Abstracts were eligible for detailed assessment if available online and reporting outcomes of interest. The search terms were: "extracorporeal membrane oxygenation" and "extracorporeal life support". No language restrictions were imposed. References of original articles were reviewed manually and cross-checked for other relevant reports. Authors of individual studies were contacted for missing data.

2.2. Selection Criteria and Quality Assessment {#sec2dot2-jcm-09-01039}
----------------------------------------------

Human studies were included if they assessed survival after VA-ECMO or weaning from VA-ECMO support instituted for refractory cardiogenic shock. Research centers were checked to avoid potential overlapping patients and those reporting on smaller samples of patients were excluded. Reviews and case reports were not considered. Two independent reviewers (M.K. and K.Z.) selected the studies for inclusion, extracted studies, as well as patient characteristics of interest and relevant outcomes. Two authors (M.K. and K.Z.) independently assessed the trials' eligibility and risk of bias. Risk of bias at the individual study level was assessed using the Risk of Bias in Not-randomized Studies-of Interventions (ROBINS-I) tool \[[@B20-jcm-09-01039]\]. Any divergences were resolved by a third reviewer (G.R.) and quantified using the approach of Cohen's kappa \[[@B21-jcm-09-01039]\].

2.3. Endpoint Selection {#sec2dot3-jcm-09-01039}
-----------------------

The primary endpoints were in-hospital/30-day survival and weaning from VA-ECMO. Secondary endpoints were in-hospital cerebrovascular events (CVE), brain death, limb complications, reoperation for bleeding, sepsis and acute kidney failure w/wo continuous veno-venous hemofiltration (CVVH). Outcome definitions were the ones adopted by the investigators of the included studies.

2.4. Statistical Analysis {#sec2dot4-jcm-09-01039}
-------------------------

Statistical analyses were performed in Comprehensive Meta-Analysis, v. 2.0 (Biostat, Englewood, NJ, USA) and Review Manager 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark). The results are expressed as pooled untransformed proportion risk ratios (RR) with their 95% confidence intervals (CI). Heterogeneity across studies was evaluated using the *I*^2^ test. To control for the anticipated heterogeneity among observational studies, absolute values and means were pooled using inverse variance random effects models. The primary endpoints were assessed in relation to the specific setting according to etiology of cardiogenic shock which included: (1) postcardiotomy shock (PCS), (2) acute myocardial infarction (AMI), (3) myocarditis and (4) mixed cohort of different etiologies including both postcardiotomy shock and AMI and other etiologies. Number needed to treat (NNT) was calculated for these subgroups. Secondary analysis focused on specific left ventricular unloading strategy: (1) intra-aortic balloon pump (IABP), (2) LV venting with cannula in left atrium or ventricle or (3) percutaneous ventricular assist device (Impella, Abiomed, Danvers, MA, USA). We performed separate analysis of studies with propensity score matching or presenting propensity score adjusted odds ratio (OR) of primary endpoints. We investigated if use of different unloading strategies had influence on complication rates, ECMO duration and weaning rates by means of meta-regression analyses \[[@B22-jcm-09-01039]\]. Similarly, we addressed the impact of hypertension, diabetes, age and gender on mortality outcome. Sensitivity analyses were performed by excluding from analyses single studies, one at a time, and repeating the calculations. Publication bias was assessed (1) by visual approach plotting log event rate against standard error in the funnel plot; and (2) by linear regression approach \[[@B23-jcm-09-01039]\].

3. Results {#sec3-jcm-09-01039}
==========

3.1. Study Selection {#sec3dot1-jcm-09-01039}
--------------------

The study selection process and reasons for exclusion of some studies are described in [Figure 1](#jcm-09-01039-f001){ref-type="fig"}. A systematic search of the online databases allowed us to screen based on title and collect 271 potentially eligible records that were retrieved for scrutiny. Of those, 204 were further excluded because they were not pertinent to the design of the meta-analysis or did not meet the explicit inclusion criteria based on their content. To avoid potential double inclusion of patients' populations, 5 studies were excluded ([Supplementary Material: Part 1](#app1-jcm-09-01039){ref-type="app"}) since they were conducted in the same institution in overlapping time frames. Sixty-three series of patients from 62 observational studies ([Supplementary Material: Part 2](#app1-jcm-09-01039){ref-type="app"}) that enrolled 7581 patients eventually were included in the analysis. Patients were divided into 2 groups: those undergoing LV unloading concomitant to VA-ECMO and those undergoing VA-ECMO alone; (3337; 44.0%) vs. (4244; 56.0%).

Patients undergoing VA-ECMO had a mean age of 57.8 years and 71.0% were male. Follow-up across the studies varied between 30-day and in-hospital survival. [Table A2](#jcm-09-01039-t0A2){ref-type="table"} details about studies and [Table A3](#jcm-09-01039-t0A3){ref-type="table"} about patients' characteristics. Risk of bias for each study across each of the seven risk of bias domains is presented in [Table A4](#jcm-09-01039-t0A4){ref-type="table"}. Overall, the studies reported either moderate or serious risk of bias. Given the overall high risk of bias along with the limited number of studies, all articles were retained for the purposes of this review. Most commonly, biases arose from (1) selection of participants for the study, and (2) subjective distribution of the participants within the study arms.

Populations included patients on VA-ECMO support for cardiogenic shock secondary to mixed etiologies (23 series, 4204 patients), PCS (22 series, 2324 patients) and AMI (14 series, 950 patients); VA-ECMO was employed for myocarditis in 4 series enrolling 103 patients.

3.2. Primary Endpoints {#sec3dot2-jcm-09-01039}
----------------------

### 3.2.1. Mortality {#sec3dot2dot1-jcm-09-01039}

All 63 included series (7581) contributed to the analysis of overall mortality; constructed funnel plot did not reveal any signs of publication bias or big study effect ([Figure 2](#jcm-09-01039-f002){ref-type="fig"}): overall in-hospital mortality was 58.9% (4466/7581). LV unloading as adjunct to ECMO support was associated with 12% lower risk of mortality compared to ECMO alone therapy: risk ratio (RR); 95% confidence intervals (CIs): 0.88 (0.82--0.93); *p \< 0*.0001; *I*^2^ = 40%; [Figure 3](#jcm-09-01039-f003){ref-type="fig"}.

The highest mortality risk benefit (25%) was observed in the subgroup of patients undergoing LV unloading + ECMO for AMI: RR (95%CIs): 0.75 (0.67--0.83); *p \< 0*.00001; *I*^2^ = 0%; NNT = 15. A mortality risk benefit of 11% was demonstrated in studies including mixed indication for LV unloading + ECMO: RR (95%CIs): 0.90 (0.81--1.00); *p* = 0.04; *I*^2^ = 48%; NNT = 11; In patients with postcardiotomy cardiogenic shock, LV unloading on top of ECMO was associated with 7% non-significantly lower mortality risk; RR (95%CIs): 0.93 (0.85--1.01); *p* = 0.09; *I*^2^ = 29%; NNT = 125. No differences were seen between LV-unloading + ECMO as compared to ECMO alone in patients with myocarditis; NNt = 9. Significant statistical differences as of extent of benefit were demonstrated between subgroups (*p*~interaction~ = 0.01). No impact on early mortality was found according to the type of cannulation, peripheral and central, in a meta-regression analysis, [Figure A1](#jcm-09-01039-f0A1){ref-type="fig"}. Similarly, these were unaffected by age, gender, diabetes and hypertension status ([Figure A2](#jcm-09-01039-f0A2){ref-type="fig"}, [Figure A3](#jcm-09-01039-f0A3){ref-type="fig"}, [Figure A4](#jcm-09-01039-f0A4){ref-type="fig"} and [Figure A5](#jcm-09-01039-f0A5){ref-type="fig"}).

### 3.2.2. Weaning {#sec3dot2dot2-jcm-09-01039}

Seventeen studies with nearly 3000 patients reported on weaning rates in subsets receiving LV unloading + ECMO as compared to ECMO therapy alone. In the overall analysis, LV unloading was associated with 35% higher probability of weaning from ECMO: RR (95%CIs): 1.35 (1.21--1.51); *p \<* 0.00001; *I*^2^ = 38%: weaning was possible in 60.4% (1789/2964) of included patients with corresponding rates of 75.3% (821/1090) and 51.7% (968/1874) for LV unloading + ECMO and ECMO alone; [Figure 4](#jcm-09-01039-f004){ref-type="fig"}. LV unloading on top of ECMO was associated with a higher chance of weaning in postcardiotomy cardiogenic shock: RR (95%CIs): 1.81 (0.99--3.29); *p* = 0.05; *I*^2^ = 0%. Differences between subgroups were not statistically significant.

3.3. Secondary Endpoints {#sec3dot3-jcm-09-01039}
------------------------

There were no apparent differences between LV unloading + ECMO vs. ECMO alone treatment regarding the secondary endpoints ([Figure A6](#jcm-09-01039-f0A6){ref-type="fig"}, [Figure A7](#jcm-09-01039-f0A7){ref-type="fig"}, [Figure A8](#jcm-09-01039-f0A8){ref-type="fig"}, [Figure A9](#jcm-09-01039-f0A9){ref-type="fig"}, [Figure A10](#jcm-09-01039-f0A10){ref-type="fig"}, [Figure A11](#jcm-09-01039-f0A11){ref-type="fig"}, [Figure A12](#jcm-09-01039-f0A12){ref-type="fig"} and [Figure A13](#jcm-09-01039-f0A13){ref-type="fig"}). Neurologic complications incidence was reported in 6 studies (596 patients) with respective 8.5% (17/199) vs. 6.0% (24/397) for ECMO + LV unloading vs. ECMO alone (RR (95%CIs): 1.03 (0.55--1.94); *p* = 0.92; *I*^2^ = 0%); [Figure A6](#jcm-09-01039-f0A6){ref-type="fig"}. Similarly, non-significant differences in terms of brain death was seen: (RR (95%CIs): 0.82 (0.34--1.97); *p* = 0.66; *I*^2^ = 7%; [Figure A7](#jcm-09-01039-f0A7){ref-type="fig"}. ECMO + LV unloading was not associated with any benefit nor harm in analysis of: limb complications (6 studies; 2695 patients): RR (95%CIs): 1.06 (0.89--1.26); *p* = 0.50; *I*^2^ = 0% ([Figure A8](#jcm-09-01039-f0A8){ref-type="fig"}); acute kidney injury (10 studies; 3178 patients): RR (95%CIs): 1.03 (0.87--1.26); *p* = 0.64; *I*^2^ = 49% ([Figure A9](#jcm-09-01039-f0A9){ref-type="fig"}); revision for bleeding: RR (95%CIs): 0.81 (0.44--1.47); *p* = 0.48; *I*^2^ = 0% ([Figure A10](#jcm-09-01039-f0A10){ref-type="fig"}); sepsis: RR (95%CIs): 0.70 (0.31--1.57); *p* = 0.38; *I*^2^ = 0% ([Figure A11](#jcm-09-01039-f0A11){ref-type="fig"}).

### 3.3.1. Analysis Stratified by LV Unloading Technique {#sec3dot3dot1-jcm-09-01039}

As secondary analysis, we assessed the impact of the different unloading techniques on mortality and weaning: 5 studies (382 patients) reported on LV unloading by direct LV venting catheters: a statistical trend of 32% reduced mortality risk was demonstrated for ECMO + LV venting as compared to ECMO alone: RR (95%CIs): 0.68 (0.45--1.03); *p* = 0.07; *I*^2^ = 28%; [Figure A12](#jcm-09-01039-f0A12){ref-type="fig"} and [Table A5](#jcm-09-01039-t0A5){ref-type="table"}. Respective mortality rates were 30.4% (24/79) vs. 60.7% (184/303) for LV unloading + ECMO and ECMO alone. No data was available about the rate of weaning in the groups receiving an LV venting. Use of IABP as an adjunct to ECMO was assessed in 56 studies (7015 patients): mortality rates were 56.4% (1791/3174) and 60.7% (2331/3841) for ECMO + IABP vs. ECMO alone; RR (95%CIs): 0.89 (0.84--0.95); *p* = 0.0004; *I*^2^ = 39%. Intra-aortic balloon pump was further associated with significant increased chance of weaning from ECMO: RR (95%CIs): 1.27 (0.14--1.42); *p \< 0*.0001; *I*^2^ = 32%); [Figure A13](#jcm-09-01039-f0A13){ref-type="fig"}. Lower, yet statistically non-significant mortality risk was found for ECMO + Impella as compared to ECMO alone (6 studies; 734 patients): RR (95%CIs): 0.85 (0.67--1.09); *p* = 0.20; *I*^2^ = 41%. Additionally, Impella device was independently associated with higher chance of weaning from ECMO: RR (95%CIs): 1.65 (1.05--2.59); *p* = 0.03; *I*^2^ = 74% ([Figure A13](#jcm-09-01039-f0A13){ref-type="fig"}).

### 3.3.2. Sensitivity Analyses {#sec3dot3dot2-jcm-09-01039}

Analyses were repeated as sensitivity for primary endpoints mortality and weaning from ECMO this time included only studies that reported effect estimates for propensity matched cohorts only: 5 studies ([Supplementary Material: Part 3](#app1-jcm-09-01039){ref-type="app"}) provided propensity adjusted estimates of mortality; pooled together, LV unloading on top of ECMO was associated with over 25% statistically significant reduction in the odds of mortality as compared to ECMO alone: OR (95%CIs): 0.74 (0.60--0.91); *p* = 0.004; *I*^2^ = 42%; [Figure 5](#jcm-09-01039-f005){ref-type="fig"}a.

Weaning rates for comparison LV unloading + ECMO and ECMO alone adjusted for propensity were reported in 4 studies ([Supplementary Material: Part 4](#app1-jcm-09-01039){ref-type="app"}); again, LV unloading on top of ECMO was associated with over 75% significantly higher odds to wean from ECMO: OR (95%CIs): 1.78 (1.40--2.28); *p \< 0*.001; *I*^2^ = 0%; [Figure 5](#jcm-09-01039-f005){ref-type="fig"}b.

Sensitivity analyses performed by deleting each study, one at a time, and repeating the calculations did not change the direction nor magnitude of the treatment effect, suggesting absence of big-study effect.

4. Discussion {#sec4-jcm-09-01039}
=============

VA-ECMO is an established treatment able to provide a mechanical circulatory support for patients in cardiogenic shock, aiming a bridge to decision or to myocardial recovery \[[@B1-jcm-09-01039],[@B2-jcm-09-01039],[@B3-jcm-09-01039],[@B4-jcm-09-01039],[@B5-jcm-09-01039],[@B6-jcm-09-01039],[@B7-jcm-09-01039],[@B8-jcm-09-01039],[@B9-jcm-09-01039]\]. Improvements in technology have mitigated the interaction between artificial surfaces of ECMO circuits and blood \[[@B24-jcm-09-01039]\]. However, other adverse effects, known as "flow-related dynamic", are strictly associated, both in central and peripheral ECMO configuration, with the retrograde direction of the flow towards a dysfunctioning left ventricle. Two major issues have been longer debated by the scientific community: the first is the difference in outcomes and hemodynamic support between the central and peripheral cannulation; the second is the clinical impact of the left ventricle unloading and the strategy to achieve a safe and effective ventricular decompression. The first issue has been already addressed by our group \[[@B25-jcm-09-01039]\]; aim of the current meta-analysis is to address the question whether myocardial unloading is beneficial or, by raising the complexity of ECMO management, futile or potentially detrimental to patients' outcomes.

ECLS institution increases the left ventricle afterload with a rise in LV end-systolic volume and reduction in LV stroke volume. If peripheral resistance and LV contractility are fixed, increase in LV end-diastolic volume is the only way to overcome the afterload via the Frank--Starling mechanism. In this case, higher levels of VA-ECMO flow cause a progressive rise in LV end-diastolic pressure, LA pressure, pulmonary capillary wedge pressure, that are associated with a further reduced LV stroke volume \[[@B26-jcm-09-01039],[@B27-jcm-09-01039],[@B28-jcm-09-01039]\]. High afterload situations with inability of LV to manage the transpulmonary blood flow, inadequate response to inotropes, complete cardiac arrest with incomplete venous drainage and aortic valve incompetence are the commonest risk factors for LV distension. Patients with severely impaired LV function and/or right ventricular dysfunction are more prone to develop an ineffective LV unloading \[[@B29-jcm-09-01039]\]. LV overload increases wall stress, myocardial oxygen consumption and induce sub-endocardial ischemia and ventricular arrhythmias, jeopardizing ventricular recovery particularly in the presence of ischemia-induced myocardial impairment. The consequence of the pressure overload may ultimately account for pulmonary congestion and edema.

If the overload is extreme and LV contractile impairment significant, the LV is unable to provide a sufficient flow against the increased afterload and the aortic valve may remain closed even during systole, causing blood stasis in the left ventricle, left atrium and aorta, and accounting for intracardiac thrombosis which has been reported in up to 6% of the cases \[[@B30-jcm-09-01039],[@B31-jcm-09-01039]\]. The LV dilatation may further induce annular dilatation and mitral valve leaflet tethering with severe functional regurgitation, thus, particularly in in patients with a history of chronic heart failure and LV dysfunction with a dilated LV, worsening the pulmonary congestion \[[@B32-jcm-09-01039]\].

Definition of LV distension during VA-ECMO is lacking in the literature. Truby et al. \[[@B33-jcm-09-01039]\] attempt to classify and grade the LVD according to the evidence of pulmonary edema on chest radiography and increased pulmonary artery diastolic blood pressure (\>25 mmHg). The latter was a surrogate of the wedge pressure evaluated in the "Should we emergently revascularize occluded coronaries for cardiogenic shock" (SHOCK) trial \[[@B34-jcm-09-01039]\]. Clinical evidence of LV distension requiring immediate decompression was inversely related to the chance of myocardial recovery. Meani et al. \[[@B32-jcm-09-01039]\] defined and graded the severity of LV loading during VA-ECMO according to hemodynamic parameters, chest X-ray and echocardiogram findings.

These differences in definitions and assessments may account for the high variability of LV distension rate in the literature. Camboni et al. \[[@B35-jcm-09-01039]\] reported need for LV decompression in 2% of the cases in more than 600 patients. A strict and longer afterload reduction (\> 24 hours), targeted lower ECMO flow and a restrictive fluid management were the strategy adopted in this large series. In Truby et al. \[[@B33-jcm-09-01039]\] the clinical and subclinical (not warranting immediate decompression) LV distension occurred in 7% and 22% of patients, respectively. Among 184 peripheral VA ECMO in the series of Meani et al. \[[@B36-jcm-09-01039]\], 5.4% required IABP placement because of a protracted closure of the aortic valve.

Drugs administration is the first line treatment of left ventricle distension. Inotropes can be administered to increase LV contractility while vasodilators may reduce the peripheral resistances and decrease left ventricle afterload. A careful fluid balance (diuretics/fluid restriction) avoiding fluid overload can reduce the risk of pulmonary edema. Ventilatory optimization, including higher PEEP, prolonged expiration time and lower tidal volume, may further improve the venous drainage.

When medical treatment is not successful, the non-pharmacological management of LV distension, acting with a "direct" or indirect" mechanism, can be obtained through a surgical or percutaneous strategy ([Figure 6](#jcm-09-01039-f006){ref-type="fig"}).

4.1. IABP {#sec4dot1-jcm-09-01039}
---------

IABP has been the most used technique to unload the left ventricle during ECMO support \[[@B37-jcm-09-01039]\]. The IABP acts with several "indirect" mechanisms reducing both the LV afterload (enhanced systolic ejection) and the LV end-diastolic pressure (enhanced left atrial and pulmonary venous unloading). The IABP induces the aortic valve opening \[[@B36-jcm-09-01039]\], improves coronary and abdominal circulation \[[@B38-jcm-09-01039]\], allows pulsatility in end organ capillary bed \[[@B39-jcm-09-01039]\], it is easy to implant and has contained costs. In animal studies the role of counterpulsation in VA-ECMO support seems controversial. Zobel \[[@B40-jcm-09-01039]\] and Sauren \[[@B41-jcm-09-01039]\] showed that IABP has beneficial effects on LV performance. Instead, Belohlávek et al. \[[@B42-jcm-09-01039]\] showed that the combination of femoral VA-ECMO and IABP could impair coronary perfusion. In clinical practice the combination ECMO/IABP was associated with improvement in hemodynamics parameters \[[@B43-jcm-09-01039],[@B44-jcm-09-01039]\], weaning rate \[[@B43-jcm-09-01039],[@B45-jcm-09-01039]\] and survival \[[@B45-jcm-09-01039],[@B46-jcm-09-01039]\].

4.2. ECPELLA {#sec4dot2-jcm-09-01039}
------------

The use of Impella in combination with VA-ECMO (also known as ECPELLA/ECMELLA) has been shown to provide improved weaning and survival rates compared to ECMO alone strategy and to established risks scores \[[@B47-jcm-09-01039],[@B48-jcm-09-01039],[@B49-jcm-09-01039],[@B50-jcm-09-01039]\]. The addition of a continuous flow vent reduces LV volumes and pressures. The LV stroke volume progressively decreases as pump flow increases, with the raise of systemic blood pressure and reduction of LA and pulmonary capillary wedge pressures. Despite the aortic valve does not open, there is no risk of blood stasis in the LV and the aortic root. The uncoupling of LV and aortic pressure is a sign of an effective unloading of the ventricle. In this situation a flat systemic pressure line is a sign of maximal unloading. Secondary changes in myocardial contractility and peripheral resistance may further enhance the LV unloading \[[@B26-jcm-09-01039],[@B50-jcm-09-01039]\]. The Impella can also reduce RV afterload and facilitate RV output and pulmonary blood flow with improvement in gas exchange \[[@B51-jcm-09-01039],[@B52-jcm-09-01039]\]. Alongside these hemodynamic features, the use of an axial flow pump may provide a circulatory support while weaning from VA-ECMO. The possibility of reducing the duration of ECLS has been reported by Scharge et al. \[[@B50-jcm-09-01039]\], however, in the experience of Pappalardo et al. \[[@B48-jcm-09-01039]\], the association of Impella and VA-ECMO prolonged the time of support but provided a successful recovery of patients who might not have survived under VA-ECMO treatment alone. The use of Impella has been associated with a significant risk of severe bleeding, vascular complications and cerebral stroke \[[@B53-jcm-09-01039],[@B54-jcm-09-01039]\]. In patients receiving the dual treatment with VA-ECMO, a higher occurrence of hemolysis has been reported \[[@B48-jcm-09-01039]\], however, no difference was generally found in terms of risk of major and minor bleeding, and cerebral stroke compared to VA-ECMO alone \[[@B47-jcm-09-01039],[@B49-jcm-09-01039]\]. These initial results seem to support an expanding use of Impella for LV unloading. Despite the evidences are still limited and coming from retrospective studies, most of the patients who underwent ECPELLA therapy were in cardiogenic shock with severely impaired LV function, were upgraded to VA-ECMO while on axial flow pump due to a progressive deterioration, or needed the implantation of Impella following significant and complicated LV distension.

4.3. Other Techniques {#sec4dot3-jcm-09-01039}
---------------------

Other unloading strategies have been reported in the literature and address the endpoints of this meta-analysis ([Table A5](#jcm-09-01039-t0A5){ref-type="table"}). Briefly, the left atrium can be drained surgically by a cannula in the left atrial roof or in the right superior pulmonary vein or percutaneously \[[@B32-jcm-09-01039],[@B55-jcm-09-01039]\] by an interatrial septostomy (septostomy usually with ballooning or stent) or a cannula attached to the ECMO venous return or to device like TamdemHeart^®^). Direct left ventricle unloading can be also achieved or by a surgical cannulation of the ventricle apex \[[@B56-jcm-09-01039],[@B57-jcm-09-01039]\] and through the mitral valve from the left atrium \[[@B56-jcm-09-01039],[@B58-jcm-09-01039]\] or percutaneously by a catheter across the aortic valve. The surgical or percutaneous pulmonary artery cannulation \[[@B56-jcm-09-01039],[@B57-jcm-09-01039]\], increasing the right-side blood drainage, will indirectly reduce the pulmonary venous return and left cardiac chamber loading. The experiences with these last unloading strategies include small populations, however, these studies found a positive impact of these adjuncts on patients' survival.

Hemodynamic responses to ECMO are different among patients and are affected by clinical presentation, associated comorbidities and the cardiovascular system coupling. This high variability may explain the difficulties in driving robust conclusions in terms of efficacy and safety of LV unloading during VA-ECMO.

Up to date and to the best of our knowledge other two meta-analysis have been published on LV unloading strategy \[[@B30-jcm-09-01039],[@B37-jcm-09-01039]\]. In 2015, Cheng et al. \[[@B30-jcm-09-01039]\] reported the impact of IABP on survival among 1517 patients (16 studies). The cumulative survival rate for patients on ECMO was 256/683 (37.5%) compared with 294/834 (35.3%) for patients with adjunctive IABP. Concomitant IABP was not associated with improved survival (RR: 1.143; 95% CI: 0.973 to 1.343; *p* = 0.10). IABP was not associated with improved survival in AMI patients (RR, 1.120; 95% CI, 0.772--1.624; *p* = 0.55), PCS (RR, 1.121; 95% CI, 0.826--1.520; *p* = 0.46) when placed prior to ECMO initiation (RR, 0.948; 95% CI, 0.718--1.252; *p* = 0.71), or when routinely inserted (RR, 1.102; 95% CI, 0.806--1.506; *p* = 0.54). Recently, Russo et al. \[[@B37-jcm-09-01039]\] reviewed 17 observational studies including 3997 patients. A total of 1696 (42%) patients received a concomitant left ventricular unloading strategy while on VA-ECMO (IABP 91.7%, percutaneous ventricular assist device 5.5%, pulmonary vein or transseptal left atrial cannulation 2.8%). Mortality was lower in patients with (54%) versus without (65%) left ventricular unloading while on VA-ECMO (RR: 0.79; 95% confidence interval (CI): 0.72 to 0.87; *p \< 0*.00001). Bleeding, limb ischemia, renal replacement therapy, multiorgan failure and stroke or transient ischemic attack were not demonstrably different in patients treated with VA-ECMO with versus without left ventricular unloading. Hemolysis was the only secondary outcome higher in patients who underwent VA-ECMO with left ventricular unloading (RR: 2.15; 95% CI: 1.49 to 3.11; *p \< 0*.0001).

4.4. Limitations {#sec4dot4-jcm-09-01039}
----------------

As analysis of only non-randomized studies, our analysis shared similar limitations with these reports which included experiences with small populations and lacked some critical information about the timing of ECMO institution, the timing of LV unloading adjunct, or the weaning protocols. Most importantly, none of the studies report exact criteria for therapy escalation e.g., addition of IABP or Impella device to ECMO. In addition, observational nature of these studies promotes selection bias. However, compared to previous meta-analyses, that present certain methodological flaws (e.g., Russo by applying the very same search strategy included 17 studies and 3997 patients), the current study, including 62 studies and more than 7500 patients, represents the first comprehensive approach addressing LV unloading strategies during ECMO support.

We found that, regardless the strategy (IABP, Impella, others) and the etiology (PCS \[[@B59-jcm-09-01039],[@B60-jcm-09-01039],[@B61-jcm-09-01039]\], AMI, other), LV unloading has a positive impact in patients' weaning, without adding any further risk of CVE, sepsis, acute renal injury requiring dialysis, limb complications and reoperation for bleeding. We have also provided a separate analysis of propensity-score matched and adjusted studies, trying, in the absence of prospective randomized data, to address the high heterogeneity of the included experiences due to different baseline populations' characteristics. This further analysis confirmed these findings favoring LV unloading techniques during VA-ECMO.

Despite the expected different flow patterns and afterload increase by central and peripheral cannulation, these two strategies were not significantly associated with a higher odds ratio risk of mortality considering the adjunct or the absence of LV unloading. However, we found a tendency in the association of higher odd ratio risk and progressively higher percentage of patients receiving peripheral cannulation, this finding couples the non-significant difference in outcomes in the PCS populations that have received a central VA-ECMO in almost 30% of the cases (less than 10% in the mixed populations, 0% in AMI patients), and suggests, within the limitations of this analysis, a more pronounced positive impact of LV unloading in the peripheral VA-ECMO setting.

The analysis of weaning, additionally included as a sensitivity analysis, might give presumptive underlying evidence of true reasons for improved survival after VA-ECMO support. The possibility of providing an adequate oxygen delivery associated with the reduction of myocardial injury and the relief of pulmonary congestion, thus enhancing arterial oxygenation and reducing pulmonary complications, may explain the higher rate of survival in patients who received an adjunct treatment able to prevent or solve left ventricular distension during VA-ECMO support.

5. Conclusions {#sec5-jcm-09-01039}
==============

During veno-arterial extracorporeal membrane oxygenation, the increase of left ventricular afterload can negatively impact the recovery from cardiogenic shock. In this meta-analysis including 7581 patients on VA-ECMO support, the adjunct of left ventricular unloading was associated with 35% higher probability of weaning and 12% lower risk of mortality.

The supplementary materials are available online at <https://www.mdpi.com/2077-0383/9/4/1039/s1>.
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PRISMA checklist.

  Section/Topic                        \#   Checklist Item                                                                                                                                                                                                                                                                                               Reported on Page \#
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Title**                                                                                                                                                                                                                                                                                                                                              
  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                          1
  **Abstract**                                                                                                                                                                                                                                                                                                                                           
  Structured summary                   2    Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   2
  **Introduction**                                                                                                                                                                                                                                                                                                                                       
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                               3
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes and study design (PICOS).                                                                                                                                                    3
  **Methods**                                                                                                                                                                                                                                                                                                                                            
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.                                                                                                                                
  Eligibility criteria                 6    Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                       3
  Information sources                  7    Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                   3
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                3
  Study selection                      9    State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                    3
  Data collection process              10   Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                   4
  Data items                           11   List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                        3--4
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                       4
  Summary measures                     13   State the principal summary measures (e.g., risk ratio, difference in means).                                                                                                                                                                                                                                4
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2^) for each meta-analysis.                                                                                                                                                      4
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).                                                                                                                                                                 4
  Additional analyses                  16   Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                             4
  **Result**                                                                                                                                                                                                                                                                                                                                             
  Study selection                      17   Give numbers of studies screened, assessed for eligibility and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               5
  Study characteristics                18   For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                 22--24 + [Supplementary material](#app1-jcm-09-01039){ref-type="app"}
  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                                                                                                                                                                                                    [Supplementary material](#app1-jcm-09-01039){ref-type="app"}
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                     [Figure 2](#jcm-09-01039-f002){ref-type="fig"}, [Figure 3](#jcm-09-01039-f003){ref-type="fig"} and [Figure 4](#jcm-09-01039-f004){ref-type="fig"} + [Supplementary material](#app1-jcm-09-01039){ref-type="app"}
  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                      5--8
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see Item 15).                                                                                                                                                                                                                              [Supplementary material](#app1-jcm-09-01039){ref-type="app"}
  Additional analysis                  23   Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[see Item 16\]).                                                                                                                                                                                      5--8
  **Discussion**                                                                                                                                                                                                                                                                                                                                         
  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users and policy makers).                                                                                                                          11--13
  Limitations                          25   Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).                                                                                                                                                12
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                      11--13
  **Funding**                                                                                                                                                                                                                                                                                                                                            
  Funding                              27   Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.                                                                                                                                                                   13
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###### 

Characteristics of included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                   Setting   Unloading Strategy       Unloading Strategy Usage (%)   N. of pts   Peripheral ECMO (%)   Distal Perfusion (*n*)   ECMO Duration             Flow Rate                                                                                                                                                                                                                                      Total Weaning Rate (%)   Bridge to VAD (*n*)   Bridge to HTx (*n*)
  ----------------------- --------- ------------------------ ------------------------------ ----------- --------------------- ------------------------ ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ --------------------- ---------------------
  Acheampong 2016         PCS       IABP                     58.3                           24          NR                    NR                       8.4 (0.8--35.4) d         NR                                                                                                                                                                                                                                             75                       1                     0

  Akanni 2018             mix       Impella                  12.9                           225         NR                    NR                       3.54 (1.64--5.97) d       NR                                                                                                                                                                                                                                             NR                       63                    NR

  Aoyama 2013             AMI       IABP                     92.1                           38          100                   NR                       126.5 ± 146.4 h           NR                                                                                                                                                                                                                                             NR                       NR                    NR

  Asaumi 2005             Other     IABP                     42.9                           14          100                   NR                       130 (42--171) h           NR                                                                                                                                                                                                                                             71.4                     1                     0

  Aso 2016                mix       IABP                     36.6                           1650        100                   NR                       2.31 d                    NR                                                                                                                                                                                                                                             65.5                     NR                    NR

  Aziz 2010               mix       IABP                     20                             10          100                   10                       5.8 d                     3.5 to 5.0 L/min                                                                                                                                                                                                                               60                       1                     1

  Beiras-Fernandez 2011   PCS       IABP                     49.3                           73          NR                    NR                       4.4 ± 4.0 d               NR                                                                                                                                                                                                                                             NR                       NR                    NR

  Beurtheret 2013         mix       IABP                     31                             87          100                   NR                       NR                        NR                                                                                                                                                                                                                                             44.8                     4                     5

  Biancari 2017           PCS       IABP (47); vent (5)      25.7                           148         60.1                  66                       6.4 ± 5.6 d               NR                                                                                                                                                                                                                                             48.6                     6                     0

  Brechot 2018            mix       IABP                     40.2                           259         100                   259                      2.2 ± 4.3 d               3.5 to 4.5\                                                                                                                                                                                                                                    55.2                     34                    21
                                                                                                                                                                                 L/min                                                                                                                                                                                                                                                                                         

  Carroll 2015            mix       IABP+Impella             15.4                           123         75                    NR                       NR                        NR                                                                                                                                                                                                                                             56.1                     2                     29

  Chen 2005               Other     IABP                     60                             10          100                   NR                       126.2 ± 56.3 h            NR                                                                                                                                                                                                                                             100                      1                     0

  Chen 2006               AMI       IABP                     86.1                           36          100                   NR                       108.5 ± 77.5 h            NR                                                                                                                                                                                                                                             69.4                     NR                    NR

  Chen 2018               PCS       IABP                     63.3                           60          100                   100                      5.3 ± 2.8 d               NR                                                                                                                                                                                                                                             48                       NR                    NR

  Cho 2018                AMI       IABP                     4.8                            42          100                   NR                       NR                        initial of 2.2 L/min/m^2^, which was subsequently regulated to maintain a mean arterial pressure of 65 mmHg                                                                                                                                    29.3                     NR                    NR

  Choi 2018               AMI       IABP                     35.2                           145         NR                    21                       2.0 d \[IQR: 1.0--4.0\]   3.3 L/min                                                                                                                                                                                                                                      62.8                     NR                    1

  Chung 2011              AMI       IABP                     70                             20          NR                    NR                       3.8 ± 4.3 d               NR                                                                                                                                                                                                                                             70                       NR                    NR

  Czobor 2016             mix       IABP (10); Impella (1)   44                             25          100                   25                       NR                        initiated at up to 4.5 L/min and adjusted                                                                                                                                                                                                      NR                       NR                    NR

  Elsharkawy 2010         PCS       IABP                     9.4                            233         33                    NR                       NR                        NR                                                                                                                                                                                                                                             NR                       28                    25

  Formica 2010            PCS       IABP                     69                             42          64.3                  10                       7.9 ± 5.3 d               to maintain a cardiac index of 2.5 l/min/m^2^                                                                                                                                                                                                  69                       NR                    NR

  Gass 2014               mix       IABP                     41.5                           135         100                   NR                       8.5 ± 7.1 d               2.5 to 4.0 L/min                                                                                                                                                                                                                               40.7                     20                    0

  Guihaire 2017           PCS       IABP (25); vent (13)     27.2                           92          84.8                  NR                       6 d                       NR                                                                                                                                                                                                                                             48                       2                     2

  Hei 2011                PCS       IABP                     16.2                           68          100                   68                       4.75 d                    40--220 mL/kg/min                                                                                                                                                                                                                              76.5                     8                     NR

  Kagawa 2012             AMI       IABP                     82.6                           86          100                   NR                       24 (8--65) h              minimum\                                                                                                                                                                                                                                       50                       NR                    NR
                                                                                                                                                                                 flow of 2.0 L/min                                                                                                                                                                                                                                                                             

  Kim 2014                AMI       IABP                     75.9                           58          NR                    NR                       68.7 ± 17.4 h             NR                                                                                                                                                                                                                                             41.4                     NR                    NR

  Lee 2016                mix       IABP                     8.7                            23          100                   NR                       98 (60--192) h            3.0 to 4.0 L/min                                                                                                                                                                                                                               NR                       NR                    NR

  Lee 2017                mx        IABP                     16.3                           135         100                   NR                       99.6 ± 103.23h            adjusted to\                                                                                                                                                                                                                                   39.3                     NR                    NR
                                                                                                                                                                                 maintain a cardiac index of 2.4 L/min/m^2^                                                                                                                                                                                                                                                    

  Li 2015                 PCS       IABP                     59.3                           123         100                   123                      4.3 d                     3.0 L/min                                                                                                                                                                                                                                      56.1                     NR                    NR

  Lin 2016                mix       IABP                     57.1                           529         100                   256                      NR                        NR                                                                                                                                                                                                                                             NR                       2                     29

  Lorusso 2016            other     IABP (34); vent (13)     59.6                           57          82.5                  63.1                     9.9 ± 19 d                NR                                                                                                                                                                                                                                             75.5                     2                     3

  Luo 2009                mix       IABP                     24.4                           45          88.9                  NR                       5.48 d                    Initially, 2.5 l/min/m2 with the condition improved, 40 mL/kg/min. adjusted the ECMO blood flow rate in time to maintain LVEF                                                                                                                  60                       5                     NR

  Mikus 2013              PCS       IABP                     92.9                           14          42.9                  14                       5 d                       to maintain cardiac index of 2.6 l/min/m^2^                                                                                                                                                                                                    50                       0                     0

  Muller 2016             AMI       IABP (96); Impella (3)   69.6                           138         NR                    132                      7 d                       NR                                                                                                                                                                                                                                             35.5                     13                    18

  Nakamura 2015           other     IABP                     95.5                           22          100                   22                       179 ± 25 h                initial flow rate was 3.0--3.5 L/min; According to the indicators of peripheral circulatory failure (e.g., arterial blood gas analysis, mixed venous oxygen saturation, lactic acid and urinary output), the flow rate of ECMO was decreased   NR                       1                     0

  Negi 2016               AMI       IABP                     60                             15          100                   NR                       1.875 d                   NR                                                                                                                                                                                                                                             53.3                     NR                    1

  Overtchouk 2018         AMI       IABP                     59.4                           106         NR                    106                      NR                        NR                                                                                                                                                                                                                                             NR                       10                    2

  Papadopoulos 2015       PCS       IABP                     21.9                           360         90                    NR                       7 ± 1 d                   50-70 mL/kg/min                                                                                                                                                                                                                                58.1                     6                     2

  Pappalardo 2016         mix       Impella                  21.7                           157         100                   39                       167 (72--286) h \*        Maximal speed                                                                                                                                                                                                                                  36.3 \*                  8 \*                  0 \*

  Park 2014               AMI       IABP                     42.7                           96          100                   NR                       NR                        initial of 2.2 L/min/\                                                                                                                                                                                                                         60.4                     NR                    NR
                                                                                                                                                                                 m2\                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                 and adjusted to maintain a mean arterial\                                                                                                                                                                                                                                                     
                                                                                                                                                                                 pressure of 65 mm Hg                                                                                                                                                                                                                                                                          

  Patel 2018              mix       Impella                  45.5                           66          100                   NR                       NR                        NR                                                                                                                                                                                                                                             56.1                     5                     NR

  Pokersnik 2012          PCS       IABP                     59.2                           49          65.3                  32                       3.8 ± 3.4 d               gradually increased to\                                                                                                                                                                                                                        55.1                     2                     0
                                                                                                                                                                                 2.0 L/min/m^2^ and adjusted as necessary to maintain\                                                                                                                                                                                                                                         
                                                                                                                                                                                 adequate hemodynamics and oxygen delivery.                                                                                                                                                                                                                                                    

  Poptsov 2014            PCS       vent                     60.9                           46          100                   100                      NR                        NR                                                                                                                                                                                                                                             NR                       NR                    NR

  Raffa 2017              PCS       IABP                     26.7                           86          34.9                  NR                       5 d                       NR                                                                                                                                                                                                                                             49                       NR                    NR

  Rastan 2010             PCS       IABP                     74.1                           517         39.3                  121                      3.28 ± 2.85 d             NR                                                                                                                                                                                                                                             63.3                     15                    5

  Ro 2013                 mix       IABP                     23.7                           253         96.4                  NR                       71.0 h                    NR                                                                                                                                                                                                                                             46.6                     NR                    3

  Russo 2010              mix       IABP                     85.7                           14          57.1                  253                      10.2 d                    NR                                                                                                                                                                                                                                             78.6                     2                     6

  Sakamoto 2012           AMI       IABP                     95.9                           98          100                   NR                       68.9 ± 62.7 h             NR                                                                                                                                                                                                                                             55.1                     0                     0

  Santise 2014            PCS       IABP                     72.2                           18          17                    NR                       6.7 ± 3.2 d               4164 ± 679 mL/min                                                                                                                                                                                                                              72.2                     NR                    NR

  Shinn 2009              mix       IABP                     33.7                           92          100                   24                       90.9 ± 126.0 h            NR                                                                                                                                                                                                                                             64.1                     NR                    NR

  Shmack 2017             mix       vent                     41.7                           48          20.1                  NR                       6.10 ± 3.81 d             2.6 L/min/m^2^                                                                                                                                                                                                                                 NR                       14                    5

  Slottosch 2012          PCS       IABP                     93.5                           77          100                   77                       79 ± 57 h                 4-7 L/min                                                                                                                                                                                                                                      62.3                     NR                    NR

  Slottosch 2017          mix       IABP                     74.8                           139         79.1                  NR                       4.9 d                     4-7 L/min                                                                                                                                                                                                                                      43.2                     NR                    15

  Smedira 2001            mix       IABP                     54.5                           202         75.7                  NR                       NR                        NR                                                                                                                                                                                                                                             58.9                     6                     42

  Tepper 2018             mix       IABP                     50                             60          0                     NR                       NR                        5.2 L/min                                                                                                                                                                                                                                      60                       10                    NR

  Unosawa 2012            PCS       IABP                     83                             47          68.1                  NR                       63.5 ± 61.5 h             2.34 L/min                                                                                                                                                                                                                                     61.7                     0                     0

  van den Brink 2017      AMI       IABP                     16.7                           12          100                   NR                       5 (1--10) d               NR                                                                                                                                                                                                                                             66.7                     1                     NR

  Wang 2013               PCS       IABP                     47.1                           87          NR                    37                       61 ± 37 h                 calculated to supply at least\                                                                                                                                                                                                                 58.6                     NR                    NR
                                                                                                                                                                                 adequate total systemic circulatory support (2.2 L/min) and to\                                                                                                                                                                                                                               
                                                                                                                                                                                 achieve a SvO~2~ of 70%                                                                                                                                                                                                                                                                       

  Weber 2017              mix       IABP                     27.3                           11          100                   11                       123.8 ± 120.9 h           NR                                                                                                                                                                                                                                             0                        NR                    NR

  Wu 2012                 mix       IABP                     73.3                           60          NR                    NR                       NR                        NR                                                                                                                                                                                                                                             63.3                     NR                    NR

  Xu 2016                 mix       IABP                     68.8                           16          NR                    NR                       119.3 ± 114.8 h           NR                                                                                                                                                                                                                                             NR                       NR                    NR

  Zhao 2015               PCS       IABP                     66.7                           24          95.8                  NR                       115.23 ± 70.17 h          49 mL/\                                                                                                                                                                                                                                        66.7                     1\*                   NR
                                                                                                                                                                                 min/kg                                                                                                                                                                                                                                                                                        

  Zhong 2017              PCS       IABP (9); vent (3)       33.3                           36          80.6                  NR                       77.5 ± 34.5 h             NR                                                                                                                                                                                                                                             66.7                     NR                    NR
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* concurrent use of LVAD and ECMO.
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###### 

Characteristics of patients.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                   Setting   Unloading Strategy       Unloading Strategy Usage (%)   N. of pts   Age (Years)        Male\   Diabetes\   Hypertension\   PCI \*\      CABG \*\*\
                                                                                                                           (%)     (%)         (%)             (%)          (%)
  ----------------------- --------- ------------------------ ------------------------------ ----------- ------------------ ------- ----------- --------------- ------------ ------------
  Acheampong 2016         PCS       IABP                     58.3                           24          41 (IQR: 22--75)   58.3    NR          NR              NA           NA

  Akanni 2018             mix       Impella                  12.9                           225         57 (46--67)        69.3    29          57              NR           NR

  Aoyama 2013             AMI       IABP                     92.1                           38          59.9 ± 13.5        92.1    NR          NR              89           11

  Asaumi 2005             Other     IABP                     42.9                           14          38.4 ± 15.8        50      NR          NR              NA           NA

  Aso 2016                mix       IABP                     36.6                           1650        NR                 69.4    NR          NR              NR           NR

  Aziz 2010               mix       IABP                     20                             10          45.3 ± 18.9        50      10          40              NR           NR

  Beiras-Fernandez 2011   PCS       IABP                     49.3                           73          49.3 ± 18.0        64.4    NR          NR              NA           NA

  Beurtheret 2013         mix       IABP                     31                             87          46 ± 15            67.8    15          24              NR           NR

  Biancari 2017           PCS       IABP (47); vent (5)      25.7                           148         65.4 ± 9.4         78.4    40          NR              NA           NA

  Brechot 2018            mix       IABP                     40.2                           259         50.2               69.9    NR          NR              NR           NR

  Carroll 2015            mix       IABP+Impella             15.4                           123         56 (41--65)        69      20          42              6            4

  Chen 2005               Other     IABP                     60                             10          37.4 ± 14.7        NR      NR          NR              NA           NA

  Chen 2006               AMI       IABP                     86.1                           36          57 ± 10            91.7    39          NR              19           78

  Chen 2018               PCS       IABP                     63.3                           60          51.4 ± 12.7        75      17          33              NA           NA

  Cho 2018                AMI       IABP                     4.8                            42          63.48 ± 11.46      66.7    41          48              100 \[74\]   0

  Choi 2018               AMI       IABP                     35.2                           145         64.6 ± 11.7        75.9    54          53              90 \[83\]    NR

  Chung 2011              AMI       IABP                     70                             20          67.7 ± 11.7        30      35          45              35           55

  Czobor 2016             mix       IABP (10); Impella (1)   44                             25          NR                 80      44          52              NR           NR

  Elsharkawy 2010         PCS       IABP                     9.4                            233         NR                 67.4    21          NR              NA           NA

  Formica 2010            PCS       IABP                     69                             42          64.3 ± 11.3        66.7    33          67              NA           NA

  Gass 2014               mix       IABP                     41.5                           135         57.3 ± 15.3        64.4    31          48              NR           NR

  Guihaire 2017           PCS       IABP (25); vent (13)     27.2                           92          64.5 (18-83)       59      NR          NR              NA           NA

  Hei 2011                PCS       IABP                     16.2                           68          49.2 ± 13.3        76.5    NR          NR              NA           NA

  Kagawa 2012             AMI       IABP                     82.6                           86          63 (56--72)        81      31          63              71           0

  Kim 2014                AMI       IABP                     75.9                           58          61.2 ± 11.3        82.8    NR          NR              NR           NR

  Lee 2016                mix       IABP                     8.7                            23          55 (40, 68)        90      52          52              65           NR

  Lee 2017                mx        IABP                     16.3                           135         59.44 ± 16.55      69.6    38          42              NR           NR

  Li 2015                 PCS       IABP                     59.3                           123         56.2 ± 11.8        65.9    NR          NR              NA           NA

  Lin 2016                mix       IABP                     57.1                           529         55.1 ± 15.3        75.4    32          35              NR           NR

  Lorusso 2016            other     IABP (34); vent (13)     59.6                           57          37.6 ± 11.8        35.1    NR          NR              NR           NR

  Luo 2009                mix       IABP                     24.4                           45          49.0 ± 14.1        76      NR          NR              NA           NA

  Mikus 2013              PCS       IABP                     92.9                           14          53.1 ± 14.3        64.3    29          64              NA           NA

  Muller 2016             AMI       IABP (96); Impella (3)   69.6                           138         55 (46--63)        80      NR          NR              81 \[72\]    NR

  Nakamura 2015           other     IABP                     95.5                           22          46.2 ± 18.7        45.5    NR          NR              NA           NA

  Negi 2016               AMI       IABP                     60                             15          57 ± 13            60      20          87              NR           NR

  Overtchouk 2018         AMI       IABP                     59.4                           106         52.7 ± 10.4        84      21          37              75 \[72\]    4

  Papadopoulos 2015       PCS       IABP                     21.9                           360         62 ± 17            76.1    42          63              NA           NA

  Pappalardo 2016         mix       Impella                  21.7                           157         53 (46--65)        83      NR          NR              36           NR

  Park 2014               AMI       IABP                     42.7                           96          NR                 77.1    61          48              81 \[63\]    10

  Patel 2018              mix       Impella                  45.5                           66          NR                 68.2    NR          NR              15           29

  Pokersnik 2012          PCS       IABP                     59.2                           49          65 ± 13            67.3    39          90              NA           NA

  Poptsov 2014            PCS       vent                     60.9                           46          42.1 ± 4.1         76.1    NR          NR              NA           NA

  Raffa 2017              PCS       IABP                     26.7                           86          65 ± 11.2          65.1    17          94              NA           NA

  Rastan 2010             PCS       IABP                     74.1                           517         63.5 ± 11.2        71.5    33          70              NA           NA

  Ro 2013                 mix       IABP                     23.7                           253         58.8 ± 15.3        60.9    23          39              NR           NR

  Russo 2010              mix       IABP                     85.7                           14          47.8 ± 16.8        71.4    NR          NR              NR           NR

  Sakamoto 2012           AMI       IABP                     95.9                           98          72 ± 12            66.3    35          45              94 \[66\]    2

  Santise 2014            PCS       IABP                     72.2                           18          49 ± 11            77.8    17          22              NA           NA

  Shinn 2009              mix       IABP                     33.7                           92          56 ± 18            64.1    24          29              NR           NR

  Shmack 2017             mix       vent                     41.7                           48          49.7 ± 19.5        47.9    NR          NR              NR           NR

  Slottosch 2012          PCS       IABP                     93.5                           77          60 ± 13            76.6    18          50              NA           NA

  Slottosch 2017          mix       IABP                     74.8                           139         58 ± 15            76.3    27          NR              NR           NR

  Smedira 2001            mix       IABP                     54.5                           202         55 ± 14            72      21          NR              NR           NR

  Tepper 2018             mix       IABP                     50                             60          53.9 ± 14.9        53.3    38          53              NR           NR

  Unosawa 2012            PCS       IABP                     83                             47          64.4 ± 12.5        74.4    38          43              NA           NA

  van den Brink 2017      AMI       IABP                     16.7                           12          63 (47--75)        83      17          42              100          0

  Wang 2013               PCS       IABP                     47.1                           87          65 ± 7             58.6    11          19              NA           NA

  Weber 2017              mix       IABP                     27.3                           11          52.5 ± 16.4        81.8    NR          NR              NR           NR

  Wu 2012                 mix       IABP                     73.3                           60          49                 66.7    43 \*\*\*   NR              48 \*\*\*    48 \*\*\*

  Xu 2016                 mix       IABP                     68.8                           16          62.3 ± 11.1        62.5    38          NR              NR           NR

  Zhao 2015               PCS       IABP                     66.7                           24          59.3 ± 11.9        79.2    25          42              NA           NA

  Zhong 2017              PCS       IABP (9); vent (3)       33.3                           36          50.4 ± 12.2        91.7    25          81              NA           NA
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* PCI as a part of managing strategy of cardiogenic shock; data presented for studies with population with acute myocardial infarction etiology; in square brackets reported is the rate of successful angioplasty. \*\* CABG as a part of managing strategy of cardiogenic shock; data presented for studies with population with acute myocardial infarction etiology. \*\*\* data for AMI patients only.
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###### 

ROBINS-I tool bias assessment.

  Study                   Bias Due to Confounding   Bias in Selection of Participants into the Study   Bias in Measurement of Interventions   Bias Due to Departures from Intended Interventions   Bias Due to Missing Data \*   Bias in Measurement of Outcomes \*   Bias in Selection of Reported Result \*   Overall Bias   Cohen's Kappa
  ----------------------- ------------------------- -------------------------------------------------- -------------------------------------- ---------------------------------------------------- ----------------------------- ------------------------------------ ----------------------------------------- -------------- ---------------
  Acheampong 2016         Serious                   Critical                                           Serious                                NA                                                   Moderate                      Moderate                             Low                                       Serious        0.83
  Akanni 2018             Moderate                  Low                                                Low                                    NA                                                   Low                           Moderate                             Moderate                                  Moderate       1
  Aoyama 2013             Serious                   Low                                                Moderate                               NA                                                   Moderate                      Serious                              Serious                                   Serious        1
  Asaumi 2005             Serious                   Moderate                                           Serious                                NA                                                   Low                           Critical                             Critical                                  Critical       0.67
  Aso 2016                Moderate                  Low                                                Critical                               NA                                                   Low                           Serious                              Moderate                                  Moderate       0.83
  Aziz 2010               Serious                   Low                                                Low                                    NA                                                   Low                           Moderate                             Moderate                                  Low            0.83
  Beiras-Fernandez 2011   Moderate                  Low                                                Low                                    NA                                                   Moderate                      Critical                             Critical                                  Critical       0.83
  Beurtheret 2013         Serious                   Moderate                                           Low                                    NA                                                   Moderate                      Low                                  Low                                       Low            1
  Biancari 2017           Low                       Low                                                Serious                                NA                                                   Moderate                      Low                                  Low                                       Low            0.83
  Brechot 2018            Moderate                  Low                                                Critical                               NA                                                   Low                           Critical                             Critical                                  Critical       1
  Carroll 2015            Moderate                  Low                                                Moderate                               NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Chen 2005               Moderate                  Moderate                                           Low                                    NA                                                   Low                           Serious                              Serious                                   Serious        0.83
  Chen 2006               Serious                   Low                                                Low                                    NA                                                   Moderate                      Serious                              Serious                                   Serious        0.83
  Chen 2018               Moderate                  Low                                                Critical                               NA                                                   Moderate                      Serious                              Serious                                   Serious        0.67
  Cho 2018                Serious                   Moderate                                           Moderate                               NA                                                   Moderate                      Serious                              Serious                                   Serious        1
  Choi 2018               Serious                   Low                                                Serious                                NA                                                   Moderate                      Serious                              Serious                                   Serious        0.83
  Chung 2011              Moderate                  Low                                                Low                                    NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Czobor 2016             Serious                   Low                                                Moderate                               NA                                                   Moderate                      Serious                              Serious                                   Serious        1
  Elsharkawy 2010         Serious                   Low                                                Low                                    NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       0.83
  Formica 2010            Moderate                  Moderate                                           Serious                                NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       0.67
  Gass 2014               Moderate                  Low                                                Critical                               NA                                                   Low                           Moderate                             Moderate                                  Moderate       1
  Guihaire 2017           Low                       Serious                                            Low                                    NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Hei 2011                Serious                   Low                                                Low                                    NA                                                   Moderate                      Moderate                             Low                                       Low            0.83
  Kagawa 2012             Moderate                  Serious                                            Serious                                NA                                                   Moderate                      Serious                              Serious                                   Serious        0.83
  Kim 2014                Moderate                  Moderate                                           Critical                               NA                                                   Moderate                      Critical                             Critical                                  Critical       0.50
  Lee 2016                Serious                   Moderate                                           Serious                                NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Lee 2017                Moderate                  Low                                                Moderate                               NA                                                   Moderate                      Serious                              Serious                                   Serious        1
  Li 2015                 Moderate                  Low                                                Low                                    NA                                                   Moderate                      Moderate                             Low                                       Moderate       0.83
  Lin 2016                Moderate                  Low                                                Critical                               NA                                                   Low                           Serious                              Serious                                   Serious        0.831
  Lorusso 2016            Low                       Moderate                                           Critical                               NA                                                   Moderate                      Moderate                             Low                                       Moderate       0.83
  Luo 2009                Moderate                  Low                                                Low                                    NA                                                   Moderate                      Moderate                             Low                                       Moderate       0.67
  Mikus 2013              Serious                   Low                                                Low                                    NA                                                   Low                           Moderate                             Moderate                                  Low            0.67
  Muller 2016             Serious                   Low                                                Low                                    NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       0.83
  Nakamura 2015           Serious                   Moderate                                           Serious                                NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Negi 2016               Moderate                  Low                                                Low                                    NA                                                   Low                           Moderate                             Moderate                                  Moderate       0.83
  Overtchouk 2018         Moderate                  Serious                                            Low                                    NA                                                   Moderate                      Critical                             Critical                                  Critical       1
  Papadopoulos 2015       Serious                   Low                                                Low                                    NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Pappalardo 2016         Moderate                  Low                                                Critical                               NA                                                   Low                           Serious                              Serious                                   Serious        0.83
  Park 2014               Moderate                  Moderate                                           Low                                    NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Patel 2018              Serious                   Low                                                Low                                    NA                                                   Low                           Moderate                             Moderate                                  Low            0.83
  Pokersnik 2012          Serious                   Serious                                            Critical                               NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Poptsov 2014            Moderate                  Serious                                            Critical                               NA                                                   Moderate                      Critical                             Critical                                  Critical       1
  Raffa 2017              Moderate                  Low                                                Serious                                NA                                                   Moderate                      Moderate                             Low                                       Moderate       0.50
  Rastan 2010             Moderate                  Low                                                Low                                    NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       0.83
  Ro 2013                 Serious                   Low                                                Critical                               NA                                                   Low                           Critical                             Critical                                  Critical       0.83
  Russo 2010              Serious                   Low                                                Low                                    NA                                                   Low                           Critical                             Serious                                   Low            0.83
  Sakamoto 2012           Moderate                  Low                                                Moderate                               NA                                                   Moderate                      Serious                              Serious                                   Moderate       0.67
  Santise 2014            Moderate                  Serious                                            Serious                                NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       0.83
  Shinn 2009              Moderate                  Low                                                Critical                               NA                                                   Moderate                      Serious                              Serious                                   Serious        0.83
  Shmack 2017             Serious                   Low                                                Serious                                NA                                                   Low                           Critical                             Critical                                  Critical       1
  Slottosch 2012          Low                       Low                                                Low                                    NA                                                   Moderate                      Low                                  Low                                       Low            1
  Slottosch 2017          Low                       Low                                                Low                                    NA                                                   Moderate                      Moderate                             Low                                       Low            0.67
  Smedira 2001            Moderate                  Low                                                Serious                                NA                                                   Moderate                      Serious                              Moderate                                  Moderate       0.83
  Tepper 2018             Moderate                  Low                                                Critical                               NA                                                   Low                           Moderate                             Moderate                                  Moderate       1
  Unosawa 2012            Serious                   Low                                                Low                                    NA                                                   Moderate                      Moderate                             Low                                       Low            1
  van den Brink 2017      Moderate                  Low                                                Critical                               NA                                                   Moderate                      Serious                              Serious                                   Serious        1
  Wang 2013               Moderate                  Critical                                           Low                                    NA                                                   Moderate                      Low                                  Low                                       Low            0.67
  Weber 2017              Low                       Critical                                           Critical                               NA                                                   Low                           Critical                             Critical                                  Critical       0.83
  Wu 2012                 Serious                   Low                                                Moderate                               NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       1
  Xu 2016                 Moderate                  Low                                                Critical                               NA                                                   Moderate                      Serious                              Serious                                   Serious        0.83
  Zhao 2015               Serious                   Critical                                           Critical                               NA                                                   Moderate                      Moderate                             Moderate                                  Moderate       0.83
  Zhong 2017              Low                       Critical                                           Low                                    NA                                                   Moderate                      Serious                              Low                                       Low            0.50

\* When multiple outcomes were reported for a study, the highest level of bias at the outcome level is reported in the table. Bias reported for comparison of peripheral vs. central extracorporeal circulation and not for a study in general.
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###### 

LV unloading strategy.

                  LA                           RSPV         Direct LV Apex   LV by RSPV    PA
  --------------- ---------------------------- ------------ ---------------- ------------- ------------
  Guihaire 2017   13 patients                                                              
  Biancari 2017                                3 patients   1 patient                      1 patient
  Poptsov 2014    19 patients (percutaneous)                                               
  Shmack 2017                                                                29 patients   
  Lorusso 2016                                 4 patients   4 patients                     2 patients

![Meta-regression showing the impact of the rate of peripheral cannulation on Log odds ratio.](jcm-09-01039-g0A1){#jcm-09-01039-f0A1}

![Meta-regression showing the impact of age distribution on Log odds ratio.](jcm-09-01039-g0A2){#jcm-09-01039-f0A2}

![Meta-regression showing the impact of gender distribution on Log odds ratio.](jcm-09-01039-g0A3){#jcm-09-01039-f0A3}

![Meta-regression showing the impact of diabetes percentage distribution on Log odds ratio.](jcm-09-01039-g0A4){#jcm-09-01039-f0A4}

![Meta-regression showing the impact of hypertension distribution on Log odds ratio.](jcm-09-01039-g0A5){#jcm-09-01039-f0A5}
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![Mortality by device.](jcm-09-01039-g0A12){#jcm-09-01039-f0A12}
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![Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of study selection process. References of included and excluded studies are listed in the [supplementary material](#app1-jcm-09-01039){ref-type="app"}.](jcm-09-01039-g001){#jcm-09-01039-f001}

![Publication bias analysis (SE: standard error).](jcm-09-01039-g002){#jcm-09-01039-f002}

![All-cause in-hospital mortality rate for patients receiving extracorporeal membrane oxygenation (ECMO) + left ventricular (LV) unloading versus ECMO alone treatment according to cardiogenic shock etiology.](jcm-09-01039-g003){#jcm-09-01039-f003}

![Weaning rate for patients receiving ECMO + LV unloading vs. ECMO alone treatment according to cardiogenic shock etiology.](jcm-09-01039-g004){#jcm-09-01039-f004}

###### 

All-cause in-hospital mortality rate (a) and weaning rate (b) from studies reporting propensity adjusted results.

![](jcm-09-01039-g005a)

![](jcm-09-01039-g005b)

![Left ventricle unloading strategies classified according to the direct or indirect, percutaneous or surgical strategies. The differences in arrows' width is intended suggesting the efficacy of left ventricle unloading (greater for direct surgical approach and Impella device). The color of the dash is intended suggesting blood oxygenation. Further techniques, not included in the picture, are the direct LV transaortic device by PulseCath device, percutaneous indirect LA drainage with TandemHeart transeptal cannula. PA: pulmonary artery; LA: left atrium; LV: left ventricle; RA: right atrium; \* achieved through right superior pulmonary vein, left atrial roof, interatrial groove; \*\* simultaneous left and right atrial drainage with the multistage cannula coming from the femoral vein and positioned transeptally.](jcm-09-01039-g006){#jcm-09-01039-f006}
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